Dyne Therapeutics (NASDAQ:DYN) reported clinical data from its ongoing Phase 1/2 trial of DYNE-101 in patients with myotonic dystrophy type 1. Shares down about 22% in early trade. DYNE-101 continued ...

“There are more than 100,000 adults with DM1 in the US and Europe ... ARTHEx also has ATX-01 in preclinical testing for myotonic dystrophy type 2 (DM2). “Although DM2 is caused by a different ...

Dr Anup Rawool Facioscapulohumeral muscular dystrophy (FSHD) is a genetic condition that affects muscle function, often ...

(RTTNews) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Myotonic dystrophy ...

Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated ...

In 2023, the analyst reported a breakdown of Myotonic Dystrophy Type 1 cases in the US, with nearly 540 congenital, 3,893 infantile, 1,515 juvenile, 39,686 adult-onset, and 8,435late-onset cases.

NEW BRIGHTON, MINN. — Twenty-year-old Giacomo Naylor, 16-year-old Lukas Naylor, 13-year-old Isadora Naylor and Gianna Naylor were all born with myotonic dystrophy — a genetic disorder that ...

Patients with myotonic dystrophy have smaller hearts, and lower systolic and diastolic blood pressures and pulse rates. They have impaired autonomic reflexes, measured by orthostatic, Valsalva ...

Keep abreast with the latest news related to Myotonic Dystrophy there are 6 news items on Myotonic Dystrophy that covers updates, breakthroughs and in-depth reports. We provide you with a free ...

We also investigate the pathogenic mechanisms of myotonic dystrophy, type 1 (DM1), an autosomal dominant ... in which failure to express adult splicing patterns causes primary features of the disease.